Literature DB >> 16083303

Selective inhibition of brain Na,K-ATPase by drugs.

A Horvat1, T Momić, S Petrović, G Nikezić, M Demajo.   

Abstract

The effect of drugs from the class of cardiac (methyldigoxin, verapamil, propranolol), antiepileptic (carbamazepine), sedative (diazepam) and antihistaminic (promethazine) drugs on Na,K-ATPase activity of plasma membranes was studied in rat brain synaptosomes. Methyldigoxin in a concentration of 0.1 mmol/l inhibits enzyme activity by 80 %. Verapamil, propranolol and promethazine in concentrations of 20, 20 and 2 mmol/l respectively, entirely inhibit the ATPase activity. Carbamazepine and diazepam in concentrations of 0.02-60 mmol/l have no effect on the activity of this enzyme. According to the drug concentrations that inhibit 50 % of enzyme activity (IC(50)), the potency can be listed in the following order: methyldigoxin promethazine verapamil ? propranolol. From the inhibition of commercially available purified Na,K-ATPase isolated from porcine cerebral cortex in the presence of chosen drugs, as well as from kinetic studies on synaptosomal plasma membranes, it may be concluded that the drugs inhibit enzyme activity, partly by acting directly on the enzyme proteins. Propranolol, verapamil and promethazine inhibitions acted in an uncompetitive manner. The results suggest that these three drugs may contribute to neurological dysfunctions and indicate the necessity to take into consideration the side effects of the investigated drugs during the treatment of various pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16083303     DOI: 10.33549/physiolres.930696

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  8 in total

1.  Cell-specific mRNA alterations in Na+, K+-ATPase α and β isoforms and FXYD in mice treated chronically with carbamazepine, an anti-bipolar drug.

Authors:  Baoman Li; Leif Hertz; Liang Peng
Journal:  Neurochem Res       Date:  2013-02-10       Impact factor: 3.996

2.  Calotropin and corotoxigenin 3-O-glucopyranoside from the desert milkweed Asclepias subulata inhibit the Na+/K+-ATPase activity.

Authors:  Salvador E Meneses-Sagrero; Luisa A Rascón-Valenzuela; Juan C García-Ramos; Wagner Vilegas; Aldo A Arvizu-Flores; Rogerio R Sotelo-Mundo; Ramon E Robles-Zepeda
Journal:  PeerJ       Date:  2022-06-02       Impact factor: 3.061

Review 3.  Na⁺,K⁺-ATPase as the Target Enzyme for Organic and Inorganic Compounds.

Authors:  Vesna Vasić; Tatjana Momić; Marijana Petković; Danijela Krstić
Journal:  Sensors (Basel)       Date:  2008-12-15       Impact factor: 3.576

4.  Effect of antihypertensive agents - captopril and nifedipine - on the functional properties of rat heart mitochondria.

Authors:  Ivana Kancirová; Magdaléna Jašová; Iveta Waczulíková; Táňa Ravingerová; Attila Ziegelhöffer; Miroslav Ferko
Journal:  Iran J Basic Med Sci       Date:  2016-06       Impact factor: 2.699

5.  Impact of tramadol and morphine abuse on the activities of acetylcholine esterase, Na+/K+-ATPase and related parameters in cerebral cortices of male adult rats.

Authors:  Abd El-Hamid Mohamed Elwy; Ghada Tabl
Journal:  Electron Physician       Date:  2017-03-25

6.  Cluster headache and intracranial aneurysm.

Authors:  Marcelo Moraes Valença; Luciana P A Andrade-Valença; Carolina Martins; Maria de Fátima Vasco Aragão; Laécio Leitão Batista; Mario Fernando Prieto Peres; Wilson Farias da Silva
Journal:  J Headache Pain       Date:  2007-10-23       Impact factor: 7.277

7.  Protective Effects of Ferulic Acid on High Glucose-Induced Protein Glycation, Lipid Peroxidation, and Membrane Ion Pump Activity in Human Erythrocytes.

Authors:  Weerachat Sompong; Henrique Cheng; Sirichai Adisakwattana
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

8.  Diminution of Oxidative Damage to Human Erythrocytes and Lymphocytes by Creatine: Possible Role of Creatine in Blood.

Authors:  Neha Qasim; Riaz Mahmood
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.